Markets

Early stage cancer biotech TCR2 Therapeutics prices IPO at $15 midpoint

TCR2 Therapeutics, a early stage biotech developing immunotherapies for various cancers, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. TCR2 Therapeutics plans to list on the Nasdaq under the symbol TCRR. Jefferies, SVB Leerink and BMO Capital Markets acted as lead managers on the deal.

The article Early stage cancer biotech TCR2 Therapeutics prices IPO at $15 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs